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A B S T R A C T
This consensus statement voices the agreement of scientiﬁc stakeholders from regulatory agencies, academia and
industry that a new framework needs adopting for assessment of chemicals with the potential to disrupt brain
development. An increased prevalence of neurodevelopmental disorders in children has been observed that
cannot solely be explained by genetics and recently pre- and postnatal exposure to environmental chemicals has
been suspected as a causal factor. There is only very limited information on neurodevelopmental toxicity,
leaving thousands of chemicals, that are present in the environment, with high uncertainty concerning their
developmental neurotoxicity (DNT) potential. Closing this data gap with the current test guideline approach is
not feasible, because the in vivo bioassays are far too resource-intensive concerning time, money and number of
animals. A variety of in vitro methods are now available, that have the potential to close this data gap by
permitting mode-of-action-based DNT testing employing human stem cells-derived neuronal/glial models. In
vitro DNT data together with in silico approaches will in the future allow development of predictive models for
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DNT eﬀects. The ultimate application goals of these new approach methods for DNT testing are their usage for
diﬀerent regulatory purposes.
There is no doubt that an optimally developed brain is a profound
asset to human functioning as well as for the sustainability and in-
tellectual depth of any society. The human brain is by far the most
advanced and complex brain in the animal world with regard to both its
structure and functionality. Although brain development in all verte-
brate species starts from a small tube of neuroectoderm, human em-
bryonic brain development proceeds in a more complex manner than
any other species. The human brain develops through a series of de-
velopmental stages that must occur in a particular sequence and at the
right time. The ﬁnal outcome on the human brain is critically depen-
dent upon the physiology of these processes, each of which might be
vulnerable to adverse eﬀects from exposures to environmental chemi-
cals or drugs.
A report by the US National Research Council (NRC) clearly docu-
ments the challenges in using rodent-based testing in general, to predict
adverse outcomes in humans (NRC, 2007). Given extensive interspecies
diﬀerences in brain morphology and function, based on speciﬁc cellular
and molecular characteristics (Gassmann et al., 2010; Harrill et al.,
2011; Baumann et al., 2016; Dach et al., 2017), and the paucity of
chemicals tested for DNT (Makris et al., 2009; Tsuji and Crofton, 2012;
Tohyama, 2016) the current reliance on DNT testing in rodents to
predict eﬀects in humans is called into question. While the US En-
vironmental Protection Agency (OPPTS 870.630) and the Organization
for Economic Co-operation and Development (OECD TG426) DNT study
guidelines exist (US EPA, 1998; OECD, 2007), including guidance for
interpreting DNT data in support of a pesticide registration developed
by the US EPA and Health Canada (Moser et al., 2016), no routine
testing for DNT is carried out in the U.S., in the EU, or elsewhere, as
DNT testing is not required by law unless triggered by neurotoxic or
endocrine eﬀects in adult rodents. These triggers may not be suﬃcient
(Bal-Price et al., 2018a) as some neurodevelopmental processes are not
present in the adult brain (Fritsche et al., 2017). At the same time,
performance of the DNT in vivo guideline studies involves the use of
large numbers of animals and is therefore cost- and time-intensive
(Crofton et al., 2012; Tohyama, 2016). These facts may contribute to
the reason why only a few environmental substances (12 in total) are
classiﬁed as human developmental neurotoxicants (Evans et al., 2016;
Grandjean and Landrigan, 2006; Bjorling-Poulsen et al., 2008).
As a consequence of the large knowledge gaps on possible neuro-
developmental toxicity of chemicals, it is highly uncertain whether we
are adequately protecting the health of our children's brains. This issue
has been recently discussed among scientists and they came to the
conclusion that a new framework must be adopted for assessing che-
micals that have the potential to disrupt brain development and control
the use of those that may pose a risk (Bennett et al., 2016; OECD, 2017;
Fritsche et al., 2017).
The rise in neurodevelopmental impairments (e.g., autism, cognitive
functions, ADHD, dyslexia) among infants and children has been sus-
pected to be caused by chemicals and/or other stressors including nu-
trition, stress, and gene-environment interactions (Julvez and
Grandjean, 2013; Grandjean and Landrigan, 2014; McDonald and Paul,
2010; Grandjean et al., 2017; Washington State Departments of Ecology
and Health., 2009).
It is now well accepted that humans have the potential to be ex-
posed to thousands of man-made compounds (Egeghy et al., 2016;
Isaacs et al., 2016) and the fact that only a small percentage of en-
vironmental contaminants have been tested for DNT, results in a critical
and urgent need to develop a cost-eﬃcient standardized alternative
approach. Many methods are now available or under development both
in vitro and in silico, that enable the study of human-speciﬁc molecular
and cellular eﬀects of chemicals, and their integration into in silico
predictive models for developmental neurotoxicity (e.g., in vitro neu-
ronal/glial models derived from human stem cells, (Q)SARs, read-
across and in silico models) (Bal-Price et al., 2015; van Thriel et al.,
2012; Aschner et al., 2017;OECD, 2017).
Due to the existing deﬁciencies in knowledge on the DNT potential
of many thousands of chemical compounds (NRC, 1984; Makris et al.,
2009; Tohyama, 2016), which for practical reasons cannot be overcome
by the current regulatory DNT guideline studies, initiatives are on-
going that promote the development of time- and cost-eﬀective in-
tegrative DNT strategies for regulatory purposes (Bal-Price et al., 2012,
2015, 2018a; Crofton et al., 2014; Smirnova et al., 2014; Schmidt et al.,
2017). Though many reservations still exist precluding a straightfor-
ward replacement of animal testing, available data from cost- and time-
eﬃcient in vitro and lower organism models are already available,
calling for consideration of their regulatory application and acceptance.
With an emerging scientiﬁc consensus, regulatory initiatives are cur-
rently ongoing (OECD, 2017) under an OECD remit with the commit-
ment of implementing concepts and tools needed to identify DNT ha-
zardous substances. Identifying reliable and eﬃcient in vitro and in silico
methods in line with the 3R principles (Replacement, Reduction and
Reﬁnement) (Russell and Burch, 1959) to identify and characterize
DNT hazards for regulatory purposes is of high priority to predict
human health concerns, as the majority of chemicals have not yet been
tested for their DNT potential (Makris et al., 2009; Tohyama, 2016).
One prominent example of successful use of an alternative model for
human hazard evaluation is the epidemic of microcephaly that occurred
in Brazil. Zika virus (ZIKV) infection was soon identiﬁed as a likely
culprit, but it also appeared that ZIKV infection could not be detected in
all microcephaly cases and that the infection did not uniformly result in
adverse eﬀects on brain development (Albuquerque et al., 2016).
However, the molecular mechanisms leading to microcephaly induced
by ZIKV infection, recently substantiated in a case control study (de
Araújo et al., 2017), were clearly evidenced using human neurospheres
derived from human induced pluripotent stem cells (hiPSCs) (Garcez
et al., 2017; Dang et al., 2016). Application of such human cell-based in
vitro approaches for assessing chemicals that could potentially aﬀect the
developing brain seems logical.
A recent approach illustrates how in vitro and in silico bioactivity
data can be combined with kinetics modeling to derive ‘risk’ estimates'
(Sipes et al., 2017). This approach, not yet applied to DNT, allows rapid
estimations of possible interactions of chemical molecules with biolo-
gical targets at environmentally relevant exposure levels. Such com-
putational predictive approaches are highly attractive alternatives, as
they can handle and integrate massive amounts and diverse types of
information to facilitate toxicity predictions at the level of complexity
of the intact human. In its report on Toxicity Testing in the 21st Cen-
tury, the National Research Council (NRC, 2007, McCray et al., 2010),
already 11 years ago called for the development of new approaches to
human health risk assessment that would rely on mechanistic under-
standing of toxicity pathways using human in vitro models and com-
puter-based modeling, rather than apical animal testing (Krewski et al.,
2010). Knudsen et al. (2013) reiterated the recommendation that in
silico approaches should be included in future toxicity assessments.
Progress for alternative DNT testing should be accelerated, in a
manner ﬁt for scientiﬁc and regulatory acceptance. In vitro screening
programs have already been initiated. For example, the U.S. EPA
ToxCast high-throughput screening assays program, where so far ap-
proximately 2000 chemicals have been examined for ~700 assay end-
points (Richard et al., 2016), and the US Federal Tox21 Program, which
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has screened nearly 8500 chemicals in about 50 selected assays (Tice
et al., 2013; Attene-Ramos et al., 2013). Unfortunately, few assays in
these programs are directly relevant to brain development. These issues
highlight the critical need for a global strategy that stimulates the de-
velopment and application of alternative models for DNT testing (Leist
et al., 2014; Bal-Price et al., 2018b).
The present special issue contributes to deﬁning the state-of-the-art
of currently available alternative approaches for DNT evaluation (Bal-
Price et al., 2018a), and it also outlines how traditional animal testing
could be improved by alignment of rodent testing with eﬀects seen in
children after neurotoxic exposures (Vorhees, 2018). The potential al-
ternative approaches relevant to DNT testing are discussed including
key neurodevelopmental processes and AOP-driven integrated ap-
proaches to testing and assessment (IATA) for DNT screening and
prioritization (Bal-Price et al., 2018a, Sachana et al., 2018), application
of non-mammalian models such as zebraﬁsh (Geier et al., 2018; Padilla
et al., 2018), developing a systems biology approach and an ontology-
driven animal-free test battery for DNT testing (Hessel et al., 2018), the
role in toxicant sensitivity of alterations in cellular metabolism during
human neurogenesis (Delp et al., 2018) and a molecular species com-
parison using methods such as the ‘Neurosphere Assay’
(Masjosthusmann et al., 2018).
Accordingly, the authors of this statement, which include stake-
holders from regulatory agencies, academia and industry, and some of
whom have contributed a manuscript to this special issue, recommend
to advance rigorously the science and regulation related to DNT testing
and the implementation of reliable animal-free human-focused me-
chanistic DNT hazard assessment by:
1. Expanding the data requirements and implementation of an alter-
native testing strategy for DNT testing in current regulatory frame-
works for industrial chemicals including pesticides, biocides and
other chemical substances occurring in our food and environment in
order to adequately protect the healthy development of our chil-
dren.
2. Developing and adopting a new OECD guidance for assessing che-
micals that have the potential to disrupt human brain development.
Here, DNT hazard characterization and prioritization for regulatory
purposes through reliable and eﬃcient in vitro and in silico methods
in line with the 3R principles in an IATA framework is of high
priority. Such alternative DNT testing should be based on test
methods assessing compounds' eﬀects on key neurodevelopmental
events relevant to human biology.
3. Populating this framework with data, through the development of a
cost-eﬃcient, standardized and holistic alternative approach for
screening large numbers of environmental contaminants to identify
those that may pose a DNT risk. Data generated by this framework
should also be leveraged to reﬁne in silico approaches with the goal
of developing reliable models predictive for human DNT eﬀects.
4. Considering implementation of alternative DNT testing models that
are already available for regulatory applications. Eﬀorts should be
put towards developing criteria to determine readiness and the ac-
ceptability of such methods and additional guidance for how the
outcome of those tests should be evaluated in the regulatory context.
5. Using in vitro mechanistic DNT data to facilitate development of
computational predictive approaches that can handle and integrate
massive amounts and diverse types of information. Including kinetic
quantitative in vitro to in vivo extrapolation models (QIVIVE) would
facilitate toxicity predictions of likely safe human exposure levels.
Yet, experimental data is needed to inform and validate such
mathematical models.
6. Closing remaining knowledge gaps through further research with
the goal of supporting more eﬀective regulation. There is agreement
in the DNT Community (Bal-Price et al., 2015, Fritsche et al., 2017)
on the necessity for further international research on testing stra-
tegies, which will require funding by all stakeholders, including
government, non-government organizations and industry.
We envisage that the present DNT special issue of TAAP on
Alternative Approaches to Developmental Neurotoxicity (DNT)
Evaluation will inspire both scientists and regulators to follow these
recommendations and to develop rational and more eﬃcient ap-
proaches to identify chemical exposures that may pose a risk to the
developing brains of future generations.
Transparency document
The http://dx.doi.org/10.1016/j.taap.2018.02.004 associated to
this article can be found, in the online version
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